Business Wire

Mary Kay Inc. Joins Forces with the Equal Rights Trust to Pioneer Research on Gender Inequality in Algorithms and Artificial Intelligence

4.10.2021 11:00:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a global leader in women’s empowerment, today announced a partnership with the Equal Rights Trust (ERT), an organization whose mission is to eliminate all forms of discrimination and ensure everyone can participate in society on an equal basis. Established in 2007, the Trust works in partnership to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. will help ERT jumpstart an innovative field of research on artificial intelligence and algorithms through a gender-based lens.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005308/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Equal Rights Trust logo (Graphic: Mary Kay Inc.)

“As a company founded on the mission to enrich the lives of women everywhere, Mary Kay is constantly on the lookout for organizations we can partner with to make an impact for gender equality globally,” said Julia Simon, Chief Legal Officer and Chief Diversity Officer of Mary Kay Inc. “We’re excited to support Equal Rights Trust on their work to help advance equality by design and beyond forge a way forward to collaborations with the private sector. Our work with ERT is specifically focused on framing the new landscape of artificial intelligence and gender equality, a growing concern in the digital age.”

Mary Kay’s support to the ERT will pioneer a new field of research on the discriminatory impact of algorithmic systems. ERT has developed and promoted models of equality impact assessment, advocating an “equality by design” approach in public and private decision making as a means to ensure non-discrimination and equality of participation. An immediate priority is to launch an initiative to establish and address the emerging discriminatory impacts of algorithmic decision-making, specifically as it relates to gender.

“The use of algorithms and artificial intelligence is spreading,” said Ariane Adam, Deputy Director of the Equal Rights Trust. “These technologies are rapidly becoming essential parts of the analytical, communication, and even legal infrastructure for our societies. Despite the global proliferation of such systems, we are only just beginning to understand the flaws, limitations, and boundaries of algorithmic decision making, especially in terms of discrimination. We’re pleased to partner with Mary Kay to shine light on the potentially discriminatory impacts of using such technologies, in particular for women.”

The delivery of the initiative can be broken into three phases:

  • Phase 1: research on emerging discriminatory impacts of the use of algorithmic-decision making in the areas of employment, access to loans, and access to housing, including a focus on the impact of women as a group particularly exposed to discrimination in these contexts.
  • Phase 2: engagement with a wide-range of actors to develop advocacy strategies to call for an equality by design approach in the design, development, roll-out and monitoring of AI technologies.
  • Phase 3: engaging with international, regional and national actors to set standards mandating an equality by design approach.

The partnership with the Equal Rights Trust is just the latest initiative supported by Mary Kay in 2021 to advocate for gender equality everywhere. For nearly 60 years, Mary Kay has been committed to empowering women and their families by partnering with organizations from around the world.

ABOUT EQUAL RIGHTS TRUST

The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this mission, it works in partnership with equality defenders – civil society organizations (CSOs), lawyers, government representatives, and others committed to using law to create an equal world – providing them with the technical, strategic and practical support they need to work for the adoption and implementation of comprehensive equality laws. Since 2007, it has supported equality defenders in almost 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org

ABOUT MARY KAY

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release

Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release

Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release

CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye